Vaxart, Inc.
VXRT- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000072444
No open-market purchases or sales by Vaxart, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $39.0K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Vaxart, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Vaxart, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Finney Kevin | Director | 244,171 | Jul 20, 2026 | 1 |
| Breitmeyer James B | Director | 87,115 | Jul 17, 2026 | 2 |
| Heron Elaine J | Director | 135,966 | Jul 17, 2026 | 2 |
| Watson W. Mark | Director | 173,525 | Jul 17, 2026 | 3 |
| Wheadon David E. | Director | 86,150 | Jul 17, 2026 | 1 |
| Grasman Jeroen Nicolaas | Chief Financial Officer | 545,605 | May 21, 2026 | 2 |
| Tucker Sean | SVP, Chief Scientific Officer | 882,811 | Mar 31, 2026 | 5 |
| Cummings James F. | Chief Medical Officer | 924,177 | Mar 31, 2026 | 5 |
| Lo Steven | President, Chief Exec Officer | 2,485,606 | Mar 26, 2026 | 4 |
| Berg Edward B | SVP, General Counsel | 755,368 | Mar 26, 2026 | 4 |
| Finney Michael J. | Director | 702,840 | Jun 16, 2025 | 0 |
| Lee Phillip E | Chief Financial Officer | 631,619 | Mar 26, 2025 | 0 |
| Yedid Robert A. | Director | 34,490 | Jun 12, 2024 | 0 |
| Floroiu Cezar Andrei | President, Chief Exec Officer | 452,735 | Mar 21, 2023 | 0 |
| Davis Todd C | Director | 125,905 | Aug 8, 2022 | 0 |
| Cherrington Julie M | Director | 6,217 | Aug 8, 2022 | 0 |
| Ahmad Fuad | Interim CFO | 5,000 | Jun 23, 2022 | 0 |
| Echerd Margaret | SVP, Principal Accntng Officer | 0 | Dec 1, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 26, 2026 (view filing) | May 22 | 4 days | Watson W. MarkDirector | PPurchase | +10.0K | $0.65 | +$6.50K | +8.1%134.1K after | |
| Dec 5, 2025 (view filing)5:46 PM ET | Nov 17 | 18 daysLate | Watson W. MarkDirector | PPurchase | +20.0K | $0.4093 | +$8.19K | +19.2%124.1K after | 2 lots |
| Nov 21, 2025 (view filing)1:21 PM ET | Nov 17 | 4 daysLate | Heron Elaine JDirector | PPurchase | +40.0K | $0.398 | +$15.9K | +70.7%96.6K after | 2 lots |
| Aug 19, 2025 (view filing)4:06 PM ET | Jul 17-Aug 15 | 33 daysLate | Finney KevinDirector | PPurchase | +166.7K | $0.3716 | +$61.9K | +437.4%204.8K after | 6 lots |
| Jul 31, 2025 (view filing)8:38 PM ET | Jul 29 | 2 days | Watson W. MarkDirector | PPurchase | +10.0K | $0.405 | +$4.05K | +10.6%104.1K after | |
| May 19, 2025 (view filing)6:49 PM ET | May 19 | Same day | Lo StevenPresident, Chief Exec Officer | PPurchase | +100.0K | $0.49 | +$49.0K | New position100.0K after | |
| Jun 20, 2024 (view filing) | Jun 18 | 2 days | Watson W. MarkDirector | PPurchase | +20.0K | $0.68 | +$13.6K | +34.4%78.1K after | |
| Dec 28, 2022 (view filing) | Dec 28 | Same day | Watson W. MarkDirector | PPurchase | +20.0K | $0.76 | +$15.2K | New position20.0K after | |
| Oct 7, 2022 (view filing) | Jan 10 | 270 daysLate | Yedid Robert A.Director | SSale | −1.50K | $6.01 | −$9.02K | −100.0%0 after | |
| Jun 23, 2022 (view filing) | Jun 22 | 1 day | Ahmad FuadInterim CFO | PPurchase | +5.00K | $3.22 | +$16.1K | New position5.00K after | |
| Dec 1, 2021 (view filing) | Nov 30 | 1 day | Echerd MargaretSVP, Principal Accntng Officer | SSale | −3.60K | $8.00 | −$28.8K | −100.0%0 after | |
| Sep 13, 2021 (view filing) | Sep 10 | 3 days | Echerd MargaretSVP, Principal Accntng Officer | SSale | −1.80K | $9.10 | −$16.4K | −100.0%0 after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Tucker SeanSVP, Chief Scientific Officer | SSale | −4.17K | $10.20 | −$42.6K | −8.7%43.9K after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Tucker SeanSVP, Chief Scientific Officer | SSale | −5.83K | $10.20 | −$59.4K | −10.2%51.5K after | |
| Aug 11, 2021 (view filing) | Aug 10 | 1 day | Echerd MargaretSVP, Principal Accntng Officer | SSale | −1.80K | $10.00 | −$18.0K | −100.0%0 after | |
| Jul 21, 2021 (view filing) | Jul 19 | 2 days | Echerd MargaretSVP, Principal Accntng Officer | SSale | −1.80K | $8.00 | −$14.4K | −100.0%0 after |